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, CHONG-JEN YU 2 1 National Taiwan University Hospital Hsinchu Branch, Taiwan, and   2 National Taiwan University Hospital, Taipei, Taiwan, Taiwan Background and Aims: Lung cancer is the leading cause of mortality in all patients with cancer. The standard first line treatment of lung adenocarcinoma harbouring sensitive epidermal growth factor receptor (EGFR) mutation is EGFR-tyrosine kinase inhibitors (TKIs). Several studies compared treatment response rate, survival, and side effect among different EGFR-TKIs and the results showed gefitinib was the least effective one among EGFR-TKIs. However, in our practice, the response rate between gefitinib and erlotinib was similar. Thus, we conduct this study for clarified this issue.
Methods: This is a retrospective cohort study of non-small lung cancer (NSCLC) patients harbouring sensitive EGFR mutation receiving 1st line EGFR-TKIs in National Taiwan University Hospital Hsinchu branch from January 1, 2010 to Dec 31, 2015. Clinical response and survival after receiving first line erlotinib or gefitinib were compared using logistic and Cox regression analyses, respectively.
Results: There were 175 patients enrolled, including 140 (80%) patients received gefitinib, and 35 (20%) patients received erlotinib. Erlotinib group were more likely to be non-adenocarcinoma cell type, and chronic kidney disease. In survival analysis, patients receiving erlotinib or gefitinib were associated with similar progression free survival (PFS) (9.5 vs 9.7 months; HR, 1.14; 95% CI, 0.75 to 1.75) and overall survival (OS) (16.8 vs 18.9 months; HR, 1.26; 95% CI, 0.78 to 2.04). However, in patient with L858R mutation, lower PFS in erlotinib compared with gefitinib (9.2 vs 6.0 months; HR, 2.43; 95% CI, 1.27 to 4.66), and OS (17.7 vs 13.2 months; HR, 3.75; 95% CI, 1.84 to 7.66) were found.
Conclusion:
In NSCLC patients harbouring sensitive EGFR mutation, first line erlotinib and gefitinib showed similar clinical response. However, in L858R subgroup, gefitinib seems more effective than erlotinib. Further large scale randomized controlled trials are necessary for confirming the result. 
